Stati Uniti - inglese - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability. studies establishing effectiveness included predominately patients with nyha functional class ii – iii symptoms and etiologies of idiopathic or heritable pah (61%) or pah associated with connective tissue diseases (23%). tadalafil tablets are contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. do not use nitrates within 48 hours of the last dose of tadalafil tablets. tadalafil tablets potentiate the hypotensive effect of nitrates. this potentiation is thought to result from the combined effects of nitrates and tadalafil tablets on the nitric oxide/cgmp pathway [see clinical pharmacology (12.2)] . co-administration of gc stimulators such as riociguat with tadalafil tablets is contraindicated. tadalafil tablets may potentiate the hypotensive effects of gc stimulators. tadalafil tablets are contraindicated in patients with a k

Stati Uniti - inglese - NLM (National Library of Medicine)

ajanta pharma usa inc. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil is used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown [see clinical studies (14.3)] .  administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2)] . tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or adcirca® ). hypersensitivity reactions

Stati Uniti - inglese - NLM (National Library of Medicine)

apotex corp. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies ( 14.3)] . administration of tadalafil tablets to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil tablets were shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology ( 12.2)] . tadalafil tablet

Stati Uniti - inglese - NLM (National Library of Medicine)

torrent pharmaceuticals limited - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph).       if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown [see clinical studies (14.3)] . administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2)] . tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or adcirca ® ). hypersensiti

Stati Uniti - inglese - NLM (National Library of Medicine)

qilu pharmaceutical co., ltd. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies ( 14.3)] . administration of tadalafil tablets to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil tablets were shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology ( 12.2)] . tadalafil tablet

Stati Uniti - inglese - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies (14.3)] . administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2) ]. tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (adcirca®* ). hypersensitivity reacti

Stati Uniti - inglese - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies (14.3)] . administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2)] . tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil or adcirca® . hypersensitivity reacti

Stati Uniti - inglese - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies (14.3)]. administration of tadalafil tablets to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil tablets were shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2)] . tadalafil tablets are contraindi

Stati Uniti - inglese - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies ( 14.3)] . administration of tadalafil tablets to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil tablets were shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology ( 12.2)] . tadalafil tablet

Stati Uniti - inglese - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph).       if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown [see clinical studies (14.3)] . administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2)] . tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or adcirca® ). hypersensitiv